ProCE Banner Activity

ACE-CL-001: Investigation of ACP-196, a Second-Generation BTK Inhibitor, in R/R CLL

Slideset Download
Conference Coverage
In this early-stage study, ACP-196 demonstrated promising activity in high-risk R/R CLL regardless of the presence of del(17p).

Released: December 15, 2015

Expiration: December 13, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen